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Glucan particles (GPs) are hollow, porous 2-4 µm microspheres derived from the 
cell walls of Bakers yeast.  The glucan content on the surface of the particles allows for 
receptor mediated cell uptake by cells with β-glucan receptors, such as macrophages and 
dendritic cells in the immune system.  GPs have been used for the delivery of 
macromolecules encapsulated inside the hollow GPs via layer-by-layer (LbL) synthesis.  
In this project, the outer surface of GPs was chemically derivatized to introduce different 
charged functional groups (i.e. amine, carboxylate, phosphate, and sulfate).  These 
derivatized GPs could be potentially used for the delivery of payload drugs covalently or 
electrostatically bound to the GP.  The modified GPs were evaluated for charged 
nanoparticle (i.e. aminated latex and carboxylated polystyrene nanoparticles) and soluble 
payload (i.e. siRNA, doxorubicin) surface binding and for efficient GP-mediated payload 
delivery to a model murine GP phagocytic cell line (NIH 3T3-D1). 
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1. Glucan Particles 
 Glucan Particles, or GPs, are porous, hollow microspheres that are prepared from 
Sacharomyces cerevisiae (Bakers yeast).  By a series of chemical extractions, the 
contents of the Bakers yeast cells are completely removed, leaving empty, hollow, porous 
microspheres (Figure 1A).  
Depending on the yeast source and the chemical conditions of the extraction, GPs 
can be prepared with different ratios of glucan, mannan, chitosan/chitin, and lipid layer.  
The glucan microspheres have an average diameter of 2-4 microns and are composed of 
1,3-D-Glucan and low levels of chitin (Figure 1B).   
The glucan content on the surface of the particles allows receptor mediated cell 
uptake by cells with β-glucan receptors (dectin-1 (D1) receptor and complement receptor 
3 (CR3))i, such as macrophages and dendritic cells in the immune system.  This ability to 
target cells in the immune system, and subsequently, cells in the blood distribution, 
makes the glucan particle an attractive drug delivery vehicle. 
1.1 Use of Glucan Particles for Macromolecular Drug Delivery 
Due to their hollow and porous nature, GPs have been used as an encapsulation 
device for the transport, delivery, and release of electrostatically bound particles.  To 
deliver payload macromolecules such as DNA, siRNA, and proteins, the payload is 
encapsulated in the glucan particle using a layer-by-layer approach to create the 
polyplexes that protect the payload molecule until it is released inside the cells.  Three 
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types of formulations as shown in Figure 2A can be prepared depending on the location 
of the payload molecule inside the GP encapsulated polyplex.   
As a DNA delivery system, GPs meet three common needs: the particles protect 
DNA against nuclease degradation, deliver the DNA through the plasma membrane into 
the nucleus of target cells, and have minimal harmful effects.  Using the GPs for DNA 
delivery in vitro it was possible to reduce the amount of DNA to about 10% of what is 
normally used with other delivery methods.  Polyethylenimine (PEI) was used as the 
trapping polymer coats in the original studies to demonstrate the use of GP for DNA 
delivery. PEI allows for DNA payload protection and for endosomal release as PEI has a 
proton-sponge effect. The limitation in the use of PEI is related to its cytotoxicity. 
Currently, research is being conducted to find polymers with equal or better efficiency 
and reduced toxicity.ii 
GPs with encapsulated DNA were synthesized using the LbL approach and 
assessed by testing the mediated delivery of the plasmid gWizGFP to NIH 3T3-D1 cells.  
DNA in the optimized yeast cell wall particle system efficiently transfects the 3T3-D1 
cells.  Greater than 50% of the cells were transfected by a 125ng DNA per 5x105 cell 
ratio when using the encapsulated DNA.  Using unencapsulated DNA/PEI 
nanocomplexes provides the same transfection efficiency when using a 16-fold higher 
concentration of plasmid DNA delivered per cell.iii 
Preparing GPs for siRNA delivery follows a very similar approach to DNA 
delivery.  The GP provides an encapsulation system that protects the siRNA from 
nuclease degradation.  A co-delivery system of GP formulations with green fluorescent 
protein (GFP) DNA and GFP siRNA showed lower transfection efficiency than a 
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codelivery system using GFP DNA and scrambled siRNA in 3T3-D1 cells.  The level of 
GFP silencing is dependent upon the siRNA concentration.iv 
A significant advance in the use of glucan particles for siRNA delivery was the 
successful oral delivery of siRNA targeting map4k4 to treat inflammation in diabetic 
mice.v  The first generation of particles consisted of five components:  tRNA core, PEI (2 
layers), Endo-Porter amphipathic peptide (EP), siRNA, and the glucan shell.  These 
components were assembled into β-1,3-D-Glucan encapsulated siRNA particles (GeRPs) 
using a LbL approach.  The EP is designed to be an alpha-helical, amphipathic peptide 
with one face being aliphatic and lipophilic and the other face being composed of basic 
amino acids, approximately 70% histidines.  The two layers of PEI showed low toxicity, 
but its inclusion in the GeRPs limited the clinical applications of the particles.  These 
original GeRPs have also been difficult to synthesis with uniformity and tend to be 
unstable.  Newer simplified GeRPs were synthesized with only two components and 
without the inclusion of the PEI trapping polymer.  Contrary to what was originally 
believed, the EP peptide is required for the silencing of targeted gene expression in 
macrophages.  Complexes of various sizes are formed when EP binds to siRNA.  These 
various complexes can silence gene expression in many types of cells, including 
macrophages and adipocytes.  The gene silencing is limited to cells that have 
phagocytosed the GeRPs in vitro.vi 
GPs have also been used for the encapsulation of small molecules, including 
Rifampicin (Rif), an antibiotic used for the treatment of tuberculosis (Tb).  Rif is a 
neutral molecule, so it cannot be trapped inside the GP using the polyplex formation or 
the LbL approach.  The synthetic method for encapsulating Rif inside GPs is a physical 
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entrapment that embeds the Rif payload in a hydrogel that partially seals the GP pores to 
prevent rapid drug release.  The hydrogels are high-water content materials that are 
prepared from cross-linked, biodegradable, biocompatible, and non-toxic polymers.  GP 
samples without a chitosan or alginate hydrogel seal release more than 90% of the 
encapsulated Rif within 30 minutes.  GPs with the hydrogel seal showed a slower release 
rate, with GPs that were sealed multiple times showing the slowest rate.  At pH 7, the 
GP-Rif formulations released up to 95% of the encapsulated Rif within 48 hours.  The 
slow release of the drug at pH 7 is evidence that the hydrogel is not sealing 100% of the 
GP pores. 
In addition to the use of the hollow cavity of GPs for drug encapsulation, the 
surface of the GP offers another option for drug binding.  Chemical derivatization of the 
GP surface is under investigation to introduce targeting ligands to increase cell tropism of 
the particles, derivatization of polymers for covalent and non-covalent binding of payload 
drugs or nanoparticles containing a payload drug. 
1.2 Surface Derivatization of GPs 
Basic synthetic procedures for the surface derivatization of glucan particles, i.e. 
reductive aminationvii and click chemistryviii, allows for many different molecules and 
polymers to be added to the surface.  These molecules can include ionic, hydrophobic, 
azide, or protein components, or more specifically, molecules such as biotin and 
cyclodextrin.  Figure 2B details the basic synthesis and surface modification strategies of 
GPs. 
The GPs can be derivatized with molecules that are used as universal surface 
acceptors for the attachment of ligands for specific chemical reactions.  An example of 
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this type of derivatization is GPs derivatized with cyclodextrin, which interact with 
ligands bearing adamantane via a host-guest interaction.  GPs derivatized with biotin can 
bind ligands through biotin-avidin or biotin-streptavidin interactions.ix 
GPs that are prepared with cationic and anionic polymers on the surface of the 
particle can serve a multitude of purposes.  These particles can bind ionic nanoparticles 
as well as ionic soluble payloads.  The ionic soluble payloads can include drugs such as 
doxorubicin, a chemotherapy drug, as well as polymers such as DNA, tRNA, and siRNA.  
The bound payloads can be delivered by the glucan particles to cells with β-glucan 
receptors.  The following experiments detail the synthesis and analysis of a library of 
cationic and anionic GPs used for electrostatic binding and delivery of ionic nanoparticles 
and soluble payloads to a model cell line (NIH 3T3-D1). 
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Materials and Methods 
 All materials, abbreviations, CAS numbers or Item numbers, and suppliers of 
products can be found in Figure 3. 
1. Quality Control of Fluorescent Nanoparticles 
The fluorescent polystyrene nanoparticles were used in six sizes: 20nm, 100nm, 
200nm, 500nm, 1µm, and 2µm.  The fluorescence excitation and emission of the 
fluorescent polystyrene nanoparticles was measured.  Excitation was measured from 400-
750nm and emission was measured from the excitation point (500nm) to 750nm.  The 
fluorescent latex nanoparticles were used in two sizes: 100nm and 1 µm.  Dilutions of the 
nanoparticles in saline (0.9%) were made and fluorescence measurements (excitation and 
emission) were made to determine the values used in future experiments using these 
nanoparticles.  Excitation of the nanoparticles was measured from 400-750nm and 
emission was measured from the excitation point (500nm) to 750nm.  The excitation and 
emission of the fluorescent polystyrene nanoparticles are detailed in Figure 4.  The 
excitation and emission of the fluorescent latex nanoparticles are detailed in Figure 5. 
2. Surface Functionalization of GPs 
2.1 Synthesis of Cationic GPs 
 GPs (200 mg) were resuspended in 20 mL of water using a polytron homogenizer, 
and additional water (20 mL) was added.  The particles were centrifuged at 3000 rpm for 
15 minutes. The water supernatant was discarded and the particles were resuspended in 
water (20 mL).  After resuspending, potassium periodate solution (8 mL of 1 mg/mL 
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solution) and additional water (12 mL) were added.  The mixture was stirred in the dark 
at room temperature overnight.  The oxidized GP sample was washed three times with 
water, and used immediately for reductive amination synthesis. 
2.1.1 GP Surface Modification with Primary, Secondary, and Tertiary Amines (PEIs, 
Chitosan, & PLL) 
 The indicated amounts of polymer and water were added to each of the oxidized 
GP samples (20 mg), the particles were resuspended and mixed at room temperature 
overnight (Figure 6A). 
After 24 hours, the samples were taken off of the rotator and allowed to rest. 
Sodium borohydride (1.2 g) was added to each centrifuge tube, and the tubes were 
allowed to sit uncapped for 24-72 hours.  The PEI-GP and PLL-GP samples were washed 
three times with water (50 mL), while the CN-GP sample was washed three times in 
0.1M acetic acid (50 mL).  Tris buffer (6.5 mL of pH 7.5 solution) was added to all tubes.  
Water was added to total 20 mL, the particles were resuspended, and the mixture was 
allowed to sit for 30 minutes.  The samples were again washed three times with water, 
resuspended in 70% ethanol, and stored overnight at -20°C for sterilization.  The samples 
were aseptically washed three times with 0.9% saline, resuspended in 20 mL of 0.9% 
saline, particles were counted with a hematocytometer and the particle suspensions were 
diluted to a concentration of 1x108 part/mL.  The cationic GP suspensions were stored at 
-20°C. 
2.1.2 Synthesis of Quaternary Amines (Quaternized Chitosan & Quaternized GP) 
 GPs and CN-GP were modified to introduce quaternary amines following a 
procedure reported for the synthesis of quaternized chitosan.x,xi 
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GP (5 mg) and CN-GP (5 mg) samples were weighed in Eppendorf tubes and 
resuspended in water (500 µL).  Glycidyltrimethylammonium chloride (GTMAC) and 
water were added to each tube in the indicated amounts (Figure 6B). 
The particle suspensions were incubated for 4 hours at 80°C, transferred to 15 mL 
centrifuge tubes with 4 mL of cold acetone, and stirred overnight at 4°C.  The sample 
were centrifuged, washed three times with acetone, resuspended in 70% ethanol, and 
stored overnight at -20°C for sterilization.  The sterile particles were aseptically washed 
three times with 0.9% saline, counted using a hematocytometer, and the particle 
suspensions were diluted to a concentration of 1x108 part/mL.  The modified GP 
suspensions were stored at -20°C. 
2.2 Synthesis of Anionic GPs 
Anionic residues cannot be directly attached to GPs or oxidized GPs. An 
alternative strategy was used to first derivatize the surface of GPs with amine groups and 
then to incorporate anionic polymers via reductive amination, EDC coupling, or 
photochemical crosslinking of the polymer to the amine groups of the surface.  
Diaminopropane (DAP) was used to generate GPs with amino groups for anionic GP 
synthesis.  DAP-GP was synthesized by a reductive amination approach as described 
previously for cationic polymers (PEI-GP, CN-GP, and PLL-GP) (Section 1.1.1).  
The indicated amounts of DAP and water were added, the particles were resuspended, 
and the mixture stirred at room temperature overnight (Figure 7A). 
The mixture was taken off of the rotator and allowed to rest.  Sodium borohydride 
(1.2 g) was added and the mixture was allowed to sit uncapped at room temperature for 
24-72 hours.  The samples were washed three times with water and the particles were 
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resuspended in Tris buffer (6.5 mL of pH 7.5 solution) and water to total 20 mL.  The 
mixture stirred for 30 minutes, and the particles were washed an additional three times 
with water.  The DAP-GP sample was lyophilized and stored at room temperature. 
2.2.1 Synthesis of Carboxylate (Alginate-GP) 
Oxidized GP was derivatized with diaminopropane (DAP), and the DAP-GP was 
used for EDC crosslinking of alginate to the GP surface.  Alginate was dissolved in water 
to make a 10 mg/mL solution.  The EDC and MES buffer were added to the alginate 
samples and stirred for 30 minutes.  The indicated amount of DAP-GP was added and the 
samples stirred overnight at room temperature (Figure 7B).   
The alginate samples were washed three times with water, the particles were 
resuspended in 70% ethanol, and stored overnight at -20°C for sterilization.  The sterile 
particles were aseptically washed three times with 0.9% saline, counted with a 
hematocytometer, and the particle suspensions were diluted to a concentration of 1x108 
part/mL and particle suspensions were stored at -20°C. 
2.2.2. Synthesis of Phosphate (tRNA-GP) 
 A solution (1 mL of 10mM) of the crosslinker sulfoSANPAH was prepared in 
PBS (pH 7).  GP (10 mg) and DAP-GP (10 mg) were weighed in Eppendorf tubes and the 
indicated amount of the sulfoSANPAH solution was added to each tube (Figure 7C).   
The particles were resuspended in the sulfoSANPAH solution and incubated at 
room temperature for 2 hours.  After 2 hours, the particles were washed three times and 
resuspended in water (1 mL).  The particles were transferred to a petri dish and tRNA  
(5 mL of a 1 mg/mL solution) was added and the particles were irradiated for 1 minute 
with a visible spectrum 350 W lamp. The samples were transferred back to 15 mL 
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centrifuge tubes, washed three times with water, resuspended in 70% ethanol, and stored 
overnight at -20°C for sterilization.  The sterile particles were aseptically washed three 
times with sterile saline, counted using a hematocytometer, and diluted to 1x108 part/mL. 
2.2.3 Synthesis of Sulfate (Dextran Sulfate & Heparin) 
 Dextran sulfate (DS) (50 mg) and heparin (Hep) (50 mg) were resuspended in 20 
mL of water and potassium periodate (12.5 mL of 1 mg/mL solution) was added.  The 
samples were stirred overnight at room temperature in the dark.  The samples were 
transferred to dialysis membranes (MW cutoff = 3000).  The membranes were placed in 
separate water baths (~1 L) for 24 hours and the water was changed four times.  The 
liquid inside the membranes was transferred to new, tared 50 mL centrifuge tubes and 
lyophilized.  The lyophilized samples of DS and Hep were dissolved in water to create 2 
mg/mL solutions. DAP-GP was dissolved in water to make a 10 mg/mL solution.  The 
indicated amounts of DS, Hep, and DAP-GP were mixed and the samples stirred 
overnight at room temperature (Figure 7D). 
Sodium borohydride (100 mg) was added to the DS-DAP-GP and Hep-DAP-GP 
samples.  These samples sat uncapped for 24 hours to allow excess H2 to escape.  The 
samples were washed three times with water and the particles were resuspended in 70% 
ethanol and stored at -20°C for sterilization.  The sterile samples were washed aseptically 
three times with 0.9% saline.  The particles were counted using a hematocytometer and 
1x108 part/mL dilutions were made. 
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3. Characterization of Cationic and Anionic GPs 
3.1 Ninhydrin Assay 
The ninhydrin assay was used to evaluate the amount of primary and secondary 
amines in synthesized compounds.  The ninhydrin reacts with primary and secondary 
amines to form Ruhemann’s purple, a blue-purple colored chromophore (Figure 8).  The 
absorbance of this ion can be measured at 570 nanometers.   
A standard solution of glycine (50 mM) in glacial acetic acid was prepared.  A 
solution of ninhydrin (2%) in DMSO was also prepared.  GP samples (1-5 mg) were 
transferred to 1 mL centrifuge tubes.  Samples were prepared from dry GPs or from 
suspensions in 0.9% saline.  The saline suspensions were centrifuged, and the saline was 
removed.  Water and ninhydrin were added to the tubes to a total volume of 200 µL.  A 
calibration curve was prepared using glycine/ninhydrin solutions. 
The tubes were incubated at 100°C for 10 minutes and then cooled at room 
temperature for 10 minutes.  Ethanol (800 µL) was added to each tube and the samples 
were vortexed.  The samples (150 µL each) were transferred to a clear-bottomed 96-well 
plate.  Additionally, 1:5 dilutions of the samples were made in the same well plate.  
Absorbance of the samples was read at 570 nm with a reference wavelength of 700 nm. 
3.2 Binding Assay 
Fluorescent ligand binding assays were used to evaluate the binding capacity of 
synthesized cationic and anionic GPs.  Two types of fluorescent ligand classes were 
evaluated for binding: (1) nanoparticles and (2) soluble polymers (i.e. tRNA, siRNA, 
PEI) or small drug molecules (doxorubicin).  
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 For example, nanoparticle binding assays were used to quantify the binding 
capacity of synthesized cationic particles.  A negative control of unmodified GP was 
used.  Saline (0.9%), GP, and payload (nanoparticles of different diameter and different 
NP/GP ratios) were mixed in 1 mL centrifuge tubes and incubated in the dark for 1+ 
hours. 
 After the incubation period of 1 hour, the unbound nanoparticles were separated 
from the GPs containing bound nanoparticles by two methods: 
(1) - Samples were centrifuged (10000 rpm for 10 minutes) and the supernatant (90 
µL) was transferred to Row A of a 96 well plate, leaving the pellet in the centrifuge 
tube.  Saline (90 µL) was added to each tube, the tubes were sonicated to resuspend 
particles and centrifuged.  The supernatant (90 µL) was transferred to row B and 
0.9% Saline (90 µL) was added.  The samples were sonicated and 100 µL from each 
tube was transferred to Row C. 
(2) - Sucrose cushion assay: To each sample was carefully added 20% sucrose (100 
µL).  The samples were centrifuged (3000 rpm for 10 minutes) and the supernatant 
(180 µL) was transferred to a 96-well plate.  Saline (180 µL) was added to each tube, 
the samples were sonicated to resuspend particles, and centrifuged (10000 rpm for 10 
minutes).  The supernatant (180 µL) was transferred the well plate and 0.9% Saline 
(180 µL) was added to each tube.  The samples were again sonicated to resuspend 
particles and 200 µL from each tube was transferred the well plate. 
 Controls totaling 100 µL were made.  In well 1, 0.9% saline was added.  Well 2 
contained a 9:1 ratio of 0.9% Saline: 1010 nanoparticles, and well 3 contained a 9:1 ration 
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of 0.9% Saline: 109 nanoparticles.  Finally, in well 4, a control of 9:1 0.9% Saline: 108 
nanoparticles was made. 
 Fluorescent carboxylated polystyrene nanoparticles were used to evaluate binding 
to cationic GPs and fluorescent amine modified latex nanoparticles were used to evaluate 
binding to anionic GPs 
3.3 Binding/Release Assay 
 Whereas the binding assay was used to evaluate the binding capacity of the 
synthesized GP compounds, the binding and release assay was used to evaluate both the 
binding capacity of the GP compound as well as the rate of release of the nanoparticles 
from GPs at different pH. 
 The indicated amounts of 0.9% saline, GP, and polystyrene nanoparticles were 
added to 1 mL centrifuge tubes and incubated for 1+ hours.  After the 1+ hour incubation 
period, the samples were centrifuged at 10000 rpm for 3 minutes and the supernatant (90 
µL) was removed and transferred to row A of a 96-well plate.  The particles were 
resuspended in 400 µL of the indicated release assay and incubated for an additional 
hour.  After the second incubation period, the samples were centrifuged, 100 µL was 
collected and transferred to row B of the well plate, leaving the pellet in the tube.  The 
remaining 300 µL were left to incubate overnight and 100 µL samples were collected at 
24 and 48 hours.  The pellets were resuspended in 100 µL 0.9% saline and transferred to 
the well plate.  The fluorescence of the supernatant and the pellets were measured from 
an excitation wavelength of 580 nm to an emission wavelength of 605 nm. 
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3.4 Zeta Potential 
 Zeta potential was used to estimate the charge of particles and nanoparticles.  The 
zeta potential of NP-GP and GP samples were determined with a Malvern Zetasizer 
Nano-ZS (Malvern Instruments, Worcestershire, UK). Solvents and buffers were filtered 
through a 0.22 µm filter before sample preparation. A suspension of particles (2x106 
particles/mL) was diluted in 1 mL of 20 mM Hepes buffer, vortexed and transferred to a 
1 mL clear zeta potential cuvette (DTS1061, Malvern). Zeta potential was collected at 25 
°C from -150 to +150 mV. The results are the average of 30 measurements collected and 
analyzed with the Dispersion Technology software 4.20 (Malvern) producing diagrams of 
zeta potential distribution versus total counts.  
3.5 Flow Cytometry (FACS) 
 FACS measurements were obtained with a Becton Dickinson FACSCalibur 
instrument (BD, Franklin Lakes, NJ). Samples were prepared for FACS analysis by 
binding of 2x107 nanoparticles to 2x106 GP particles. The samples were washed from 
unbound nanoparticles and resuspended at 2x106 GP/mL in PBS. Unmodified GPs were 
used as negative controls and rhodamine labeled GPs as the positive control. The 
particles were analyzed with an FL4 laser at 605 nm by collecting an average of 15000 
measurements. Gating and analysis was performed using FlowJo 6.4.2 software. 
4. Applications of Surface Derivatized GPs 
4.1 Use of Cationic GPs for DNA Transfection 
 Cationic GPs were evaluated for efficient delivery of plasmid gWizGFP DNA 
into 3T3-D1 cells. 
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 The indicated amounts of saline, GP, and gWizGFP DNA were mixed in 
Eppendorf tubes and incubated at room temperature in the dark for 1 hour.  10k PEI was 
added, while vortexing, to the indicated tubes and the samples incubated for an additional 
20 minutes.  The samples were washed with saline and the supernatant (90 µL) was 
discarded.  The samples were resuspended in saline (90 µL) and DMEM (250 µL) was 
added.  The samples were transferred to the indicated wells and the cells incubated 
overnight at 37˚C and 5% CO2.  After 24 hours, the media was changed and the cells 
incubated an additional 24 hours.  The cell were fixed with 1% formalin and evaluated 
for frequency (% fluorescent cells) of green fluorescent protein (GFP) transfection. 
4.2 Use of Anionic GPs for Doxorubicin Delivery 
 Doxorubicin (Dox), a cationic drug used for cancer chemotherapy, was used in 
binding assays and cell uptake experiments. 
 The indicated amounts of saline, GP, and Dox were mixed in Eppendorf tubes and 
incubated at room temperature in the dark for 1 hour.  The samples were washed with 
saline and the supernatant (180 µL) was removed.  The pellet was resuspended in saline 
(180 µL) and DMEM (250 µL) was added.  The samples were transferred to the indicated 
wells and incubated overnight at 37˚C and 5% CO2.  The cells were fixed with 1% 
formalin and evaluated for evidence of GP mediated delivery of Dox. 
5. Click Chemistry Derivatization of GPs 
A click chemistry reaction was used to modify the surface functionality of the 
GPs.  Before carrying out the click chemistry reaction, GPs and azido-GPs with 
fluorescent tRNA/PEI cores were synthesized.  To make the fluorescent particles, the 
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indicated amount of tRNA solution was added to 1mg blanks of GP and azido-GP in 
microcentrifuge tubes (Figure 9). 
Each tube was mixed with a heat-sealed blunt pipet tip to form a uniform wet 
paste.  The samples were incubated for 1+ hours at 50°C.  After the incubation period, the 
samples were lyophilized.  Water (5 µL) was added and the samples were again incubated 
for 1+ hours at 50°C followed by lyophilization.  After the second lyophilization, 0.1% 
PEI (5 µL) was added to the microcentrifuge tubes, a wet paste was achieved, and the 
samples were incubated for 10 minutes at room temperature.  The indicated amount of 
PEI (Table 9) was added to the samples.  The samples were then sonicated and incubated 
at room temperature for 30 minutes.  After this incubation period, the samples were 
centrifuged, the supernatant was removed, and the particles were resuspended in 0.9% 
saline (1 mL).  The samples were centrifuged, the saline was removed and the samples 
were resuspended in 70% ethanol (1 mL) and stored overnight at -20°C for sterilization.  
After sterilization, the samples were washed three times with sterile 0.9% saline, the 
particles were counted and 1x108 particles/mL dilutions were prepared.  The final 
samples were stored at -20°C. 
 The fluorescent tRNA core samples were used in the click chemistry synthesis.  
The 1x108 particles/mL solutions (500 µL) were transferred to new 1 mL centrifuge 
tubes.  The samples were centrifuged, the saline supernatant was removed, and the 
particles were resuspended in sterile water (500 µL).  The fluorescent alkyne (500 µL) 
was added to each tube.  Additionally, CuSO4 (15 µL of 10 mg/mL solution) and sodium 
ascorbate (30 µL of 5 mg/mL solution) were added to each centrifuge tube.  The reaction 
was stirred in the dark at room temperature for 3+ hours.  After 3+ hours, the samples 
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were centrifuged, the supernatant was removed, and the samples were washed three times 
with water.  The particles were resuspended in 0.9% saline (1 mL).  Fluorescence was 




Results and Discussion 
1.  Synthesis of Cationic and Anionic GPs 
Cationic polymers such as PEI have been added to the surface of GPs, creating a 
payload-binding mechanism.  In addition to cationic polymers, anionic polymers can also 
be added to the surface of GPs.  In order to attach the components of nanoparticles to the 
outside of the glucan particles, the GP must first be oxidized to activate the carbohydrate 
surface.  After the oxidation, cationic groups can be covalently grafted to the surface, 
while the addition of most anionic groups need an additional linker such as 
diaminopropane, DAP, in order to be attached to the surface of the GP. 
Once functional groups have been added to the surface of the GP, the particles 
can be further modified to better serve the binding needs.  For example, chitosan attached 
to the surface of GP can be modified in order to produce quaternary amines. 
The success of the synthesis of the cationic and anionic GPs was characterized 
using the ninhydrin assay and zeta potential measurements. 
1.1  Ninhydrin Assay Results 
To determine the amount of primary and secondary amines in synthesized GPs, 
the ninhydrin assay was used.  The ninhydrin reacts with primary and secondary amines, 
creating the chromophore Ruhemann’s purple.  This chromophore can be measured using 
absorbance.  The results of the ninhydrin assay, including unmodified GP and 
synthesized GP compounds, are summarized in Figure 10. 
The ninhydrin assay results show that most GPs modified by reductive amination 
have a higher molar content of amines as compared to the unmodified GP control.  An 
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unmodified GP is composed of 1-2% chitosan, the amines of the chitosan account for the 
low levels of NH2 measured in the GP control.  A slight increase in the NH2 content for 
the PEIs, CN, and PLL modified particles confirms surface modification.  A limitation of 
the ninhydrin assay is that it does not react with tertiary or quaternary amines.  Overall, 
the measurements of µmol NH2 represent the modified particles, with the exception of 
DAP-GP.  DAP-GP should have a relative high level of NH2, but measurements show 
that the concentration of amines is very low.  The size of the DAP molecule may be 
contributing to this measurement, as the DAP may be embedded in the GP matrix, where 
steric hindrance limits reaction with ninhydrin. 
1.2  Zeta Potential Results 
To determine an estimate of the charge of the glucan particles, zeta potential 
measurements were used.  The particles were suspended in filtered Hepes buffer and 
measured using a Zetasizer at 25 °C from -150 to +150 mV.  The zeta potential 
measurements of unmodified GP and synthesized cationic and anionic GP compounds are 
summarized in Figures 11A and 12A.  All values are +/- 5mV. 
The unmodified GP control has a neutral zeta potential, and shifts of more than 
10mV to positive zeta potential confirms the synthesis of cationic GPs (Figure 11A).  An 
example of cationic surface modification confirmed by zeta potential is shown in Figure 
11B.  The zeta potential measurements are an estimate of the charge of the particle.  An 
ideal particle will not aggregate unless centrifuged.  GPs, however, aggregate over time.  
The particle aggregation inside the zeta potential cell can have a negative effect on 
measuring the true potential of the particle.  Aggregation of modified GPs masks some of 
the surface charge of the particles, resulting in a smaller shift of zeta potential. 
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 Anionic polymers cannot be immediately added to the surface of GPs or oxidized 
GPs.  The strategy used to create modified anionic GPs was to derivatize the surface with 
amine groups so the anionic polymers could be incorporate using reductive amination, 
EDC coupling, or photochemical crosslinking.  DAP-GP was successfully prepared as 
confirmed by its cationic (19.6 mV) zeta potential.  For some particles the shift in zeta 
potential to anionic value was minimal indicating low yield of polymer grafting to the 
DAP-GP.  The reductive amination was used to synthesize the DS-DAP-GP (12.1 mV) 
and Hep-DAP-GP (10.0 mV) particles.  The reductive amination gives lower yields and 
is not very efficient compared to the other strategies.   
The successful derivatization of particles with the alginate polymer did depend on 
using DAP; the reaction was more efficient than DS-DAP-GP (12.1 mV) and Hep-DAP-
GP (10.0 mV) due to the EDC crosslinking.  Crosslinking by EDC will not take place 
unless amine groups are on the surface of the GP.  Thus, the Alg-DAP-GP (-21.1 mV) 
and AlgL-DAP-GP (-18.2 mV) successfully bind nanoparticles and soluble polymers, 
while the Alg-GP (-0.71 mV) and AlgL-GP (-6.54 mV) do not.  The sequential 
modification of GP to produce DAP-GP and finally Alg-DAP-GP was confirmed by zeta 
potential (Figure 12B). 
The successful synthesis of the tRNA derivatized particles did not depend on 
DAP.  The crosslinker, sulfoSANPAH, is a photo-crosslinker, which reacts with amine 
groups such as DAP, but also with hydroxyl groups that can be found of the surface of 
the unmodified GP.  This is shown by the zeta potential shifts of tRNA-GP (-15.9 mV) 
and tRNA-DAP-GP (-16.8 mV). 
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2. Characterization of Cationic and Anionic GPs 
Using the ninhydrin assay and zeta potential measurements, the synthesis of 
cationic and anionic particles was considered a success.  The binding capacity of the 
ionic GPs was tested using binding experiments with nanoparticles. 
2.1 Nanoparticles 
In binding experiments with synthesized GPs, two types of nanoparticles (NPs) 
were used.  When testing cationic GPs, anionic (carboxylated) fluorescent polystyrene 
nanoparticles were used.  Fluorescent cationic (amine) latex nanoparticles were used 
when testing the binding capacity of anionic GPs. 
2.2 Nanoparticle Binding to GPs 
2.2.1 Polystyrene Nanoparticles 
To determine the binding capacity of the cationic GPs, all sizes (0.02, 0.1, 0.2, 0.5 
1, and 2 µm) of polystyrene nanoparticles were bound to the synthesized GPs.  The 
nanoparticles were incubated with the GPs for one hour, and the fluorescence of the 
supernatant, wash, and pellet were measured from 580-605 nm.  Figures 13A, 14A, and 
15A detail the measured binding capacity of the three smallest sizes of fluorescent 
nanoparticles.   
The binding capacity is defined as the ratio of nanoparticle concentration 
determined from fluorescence emission measurements divided by the target input of 
nanoparticle concentration. measured  NP  concentration  in  pelletinput  NP  concentration   =   Binding  Capacity 
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Accurate measures of binding capacity for the larger nanoparticle sizes (0.5, 1, 
and 2 µm) were not quantified due to the aggregation and co-precipitation of free 
nanoparticles. 
Particles that showed clear evidence of polystyrene nanoparticle binding were 
transferred to slides and examined under a fluorescence microscope at 100x.  Figures 
13B, 14B, and 15B show evidence of selective binding of 20nm, 100nm, and 200nm 
polystyrene nanoparticles to cationic GPs, but not the unmodified GP control.   
Additionally, to determine the binding capacity of fluorescent particles to 
unmodified GP and synthesized cationic GPs, flow cytometry was used.  The 
nanoparticles were incubated with the GPs for one hour, the pellet was resuspended in 
PBS, and the FACS measurements were made with a Becton Dickinson FACSCalibur 
instrument.  The results show that unmodified GPs do not bind the fluorescent 
polystyrene and the modified GPs do bind the nanoparticles (Figure 16). 
Finally, to determine an estimate of the shift in surface charge of the cationic GPs 
bound to fluorescent (anionic) polystyrene nanoparticles, zeta potential was used.  The 
nanoparticles were incubated with the GPs for one hour, the pellet was resuspended in 
filtered Hepes buffer and measured using a Zetasizer at 25 °C from -150 to +150 mV.  
The results are detailed in Figure 17A. 
The binding assay and microscopy results regarding neutral, unmodified GP were 
confirmed by zeta potential measurements.  The zeta potential of the neutral GPs did not 
shift in the sample containing GPs and 200nm r-PS nanoparticles.  In addition, the peak 
of the free NPs was measured in this sample at ~ -60 mV.  For Cationic GPs, zeta 
potential confirms (1) binding of the anionic nanoparticles as the zeta potential of the 
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cationic GP shifts to an anionic value, and (2) the successful separation of unbound NPs 
from the NP-GP sample as there is only one peak (NP-GP) and no evidence of free 
polystyrene nanoparticles at ~ -60 mV.  As a specific example, the zeta potential of CN-
GP before and after binding to polystyrene nanoparticles is illustrated in Figure 17B. 
The cationic GPs were also bound to the larger polystyrene nanoparticles: 500nm, 
1µm, and 2µm.  However, unbound nanoparticles aggregated with the GPs in the pellet, 
so accurate fluorescence measurements for binding capacity could not be collected.  The 
samples were examined at 100x using a fluorescence microscope for evidence of 
nanoparticle binding.  Figure 18 details cationic GPs binding the larger nanoparticles. 
2.2.2 Latex Nanoparticles 
To determine the binding capacity of the anionic GPs, one size of latex 
nanoparticles (100nm) was bound to the synthesized anionic GPs.  The nanoparticles 
were incubated with the GPs for one hour, and the fluorescence of the supernatant, wash, 
and pellet were measured from 520-540 nm.  The latex nanoparticles easily aggregated, 
resulting in an inability to accurately measure fluorescence, binding capacity, and zeta 
potential.  The collected results, including the quality control experiments of the free 
particles, did not give expected results.  The zeta potential of the nanoparticles bound to 
GPs (Figure 19C) confirms the particle aggregation, as the measurement shows data 
representative of the buffer control.  
Due to the aggregation of the latex nanoparticles, quantitative data for the binding 
capacity of the anionic GPs was not easily collected (Figure 19A).  Latex binding to 
anionic GPs was confirmed only by qualitative microscopy evaluation of the anionic GP 
samples and the unmodified GP control. 
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The aggregation of both bound and unbound latex nanoparticles in the pellet did 
not allow for accurate fluorescence readings.  Samples were transferred to slides and 
examined under a fluorescence microscope at 100x.  Figure 19B shows evidence of 
binding of 100nm latex nanoparticles to Alg-DAP-GP, but not the GP control. 
2.3 Polymer Binding to GPs 
When binding experiments using nanoparticles proved to be successful, the 
particles were used in binding experiments using fluorescent polymers or soluble 
payloads, including nucleic acids. 
2.3.1 Nucleic Acids binding to cationic GPs 
To determine the binding capacity of the cationic GPs, three different anionic 
polymers were used, Cy3-sirRNA, r-DNA, and r-tRNA.  The polymers were incubated 
with the GPs for one hour, and the fluorescence of the supernatant, wash, and pellet were 
measured from 540-573 nm.  The binding capacity results in Figure 20A proved selective 
binding of anionic siRNA to cationic GPs.  
The binding capacity is larger for the quaternary GP which correlates with the 
expected result that a particle modified with quaternary amines has higher binding 
affinity than particles modified with primary or secondary amines.  The GP control did 
not bind a significant amount of siRNA. 
Particles that showed clear evidence of Cy3-siRNA binding were transferred to 
slides and examined under a fluorescence microscope at 100x. Figure 20B shows 
evidence of binding of Cy3-siRNA polymer. 
Finally, to determine an estimate of the shift in surface charge of the cationic GPs 
bound to fluorescent (anionic) Cy3-siRNA, zeta potential was used.  The polymer was 
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incubated with the GPs for one hour, the pellet was resuspended in filtered Hepes buffer 
and measured using a Zetasizer at 25 °C from -150 to +150 mV.  The zeta potential 
results for GPs +/- Cy3-siRNA are detailed in Figure 20C. 
The second polymer, fluorescently labeled DNA (r-DNA) was also bound to 
cationic GPs at a ratio of 1 µg/1x106 GP.  The binding results in Figure 21A do not 
clearly confirm selective binding of r-DNA compared to the neutral GP control.  A high 
concentration of r-DNA was necessary to obtain a strong fluorescent signal, and it is 
likely some of the r-DNA precipitated during the binding assay.  Additional work is 
required to confirm binding of r-DNA to cationic GPs by using a more fluorescent 
sample so that the experiment can be done at similar concentrations used for siRNA. 
Only the 25k PEI-GP particles show evidence of binding of r-DNA higher than 
that of the unmodified GP.  These particles were transferred to slides and examined under 
a fluorescence microscope at 100x.  Figure 21B shows evidence of binding of the  
r-DNA polymer to both cationic GP and the neutral GP control. 
The r-DNA was most likely absorbed into the center of some GPs, resulting in the 
binding capacity of unmodified GP being higher than some of the synthesized cationic 
glucan particles.   
 The third polymer, fluorescently labeled tRNA (r-tRNA) was also bound to 
cationic GPs at a ration of 1 µg r-tRNA/1x106 GPs.  Similarly to DNA, the results in 
Figure 22A do not show an improvement in binding capacity of tRNA to cationic GPs 
compared to the neutral GP control.  Again, the high concentration and quality of the 
polymer affected the efficiency of binding. 
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Particles that showed clear evidence of r-tRNA binding were transferred to slides 
and examined under a fluorescence microscope at 100x.  Figure 22B shows evidence of 
binding of r-tRNA. 
The r-tRNA was also most likely absorbed into the center of some GPs, resulting 
in the binding capacity of unmodified GP being higher than some of the synthesized 
cationic glucan particles.  Additionally, the tRNA and DNA could be precipitating and 
randomly binding to the unmodified GP surface or forming aggregates in the pellet.  The 
age of the nucleic acid samples could also be a factor as the older samples are less stable. 
2.3.2 10k Polyethyleneimine binding to anionic GPs 
To determine the binding capacity of the anionic GPs, one cationic polymer was 
used, r-10k PEI.  The polymers was incubated with the GPs for one hour, and the 
fluorescence of the supernatant, wash, and pellet were measured from 540-573 nm.  
Anionic GP binding assays used GPs in the amount of 1x108 part/mL and r-10k PEI in a 
concentration of 0.1 mg/mL (1 µg PEI/1x106 GPs).  The results shown in Figure 23A 
confirm selective binding to anionic GPs. 
The expected results, based on surface charge, for binding capacity of anionic 
GPs predict that the heparin and dextran sulfate GPs will have the highest binding 
capacity, followed by the tRNA GPs, and the alginate GPs were expected to have the 
lowest binding capacity.  However, of the anionic GPs, the alginate-GPs showed the 
highest binding capacity.  The efficient synthesis of the Alg-DAP-GP and AlgL-DAP-GP 
particles using EDC crosslinking provides a high yield of particles with alginate covering 
the surface.  The photo-crosslinking of the tRNA-GP and tRNA-DAP-GP particles using 
sulfoSANPAH was also an efficient synthesis, and the tRNA particles also bound 
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cationic polymers well.  The reductive amination synthesis used to prepare the DS and 
Hep GPs was not nearly as efficient as the crosslinking reactions, making the binding 
capacity of the DS-DAP-GP and Hep-DAP-GP lower than the rest of the anionic 
particles. 
Particles that showed clear evidence of r-10k PEI binding were transferred to 
slides and examined under a fluorescence microscope at 100x.  Figure 23B shows 
evidence of binding of r-10k PEI polymer. 
3. Applications of Cationic and Anionic GPs 
After successful binding experiments with the polymers and soluble payloads, the 
cationic GPs were used in DNA transfections and the anionic GPs were used in uptake 
experiments using a cationic cancer drug. 
3.1 DNA Transfection with Cationic GPs 
To determine the transfection efficiency of cationic GPs, the particles were bound 
to gWizGFP DNA and delivered to 3T3-D1 cells.  The cells incubated with the DNA for 
48 hours and were evaluated for frequency (% fluorescent cells) of green fluorescent 
protein (GFP) transfection.  Transfection efficiency was calculated as the percentage of 
fluorescent cells (cells expressing GFP) in a field containing approximately 200 cells.  
Figure 24A details transfection efficiency of cationic GPs with a DNA concentration of 
0.5µg/1x106 particles.   
To determine the concentration of DNA that will provide the best transfection 
efficiency, the concentration of DNA was varied in transfection experiments.  Figure 24B 
details the transfection efficiency of CN-GP with varying concentrations of DNA. 
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The CN-GP samples from the DNA transfections were examined on a 
fluorescence microscope for evidence of GFP DNA transfection.  The CN-GP gave the 
best transfection results of all synthesized cationic GPs.  The chitosan on the surface of 
the GP binds the plasmid DNA used for transfection, but it binds much less tightly than 
other cationic GPs, such as 10k PEI-GP, 25k PEI-GP, and Q-GP.  The CN-GP will 
release the plasmid DNA more quickly than the other cationic GPs because the DNA is 
less tightly bound to the chitosan.  Figure 24C shows the difference in DNA transfection 
efficiency with unmodified GP and CN-GP. 
3.2 Doxorubicin (Dox) Delivery with Anionic GPs 
To determine the binding capacity of the anionic GPs, one drug was used, 
doxorubicin (Dox).  The Dox was incubated with the GPs for one hour, and the 
fluorescence of the supernatant, wash, and pellet were measured from 480-550 nm.  
Figure 25A shows a significantly low binding capacity (less than 20% of Dox input was 
bound to all particles).  Dox binding to the anionic GPs was confirmed by qualitative 
fluorescent microscopy evaluation of all samples (Figure 25B). 
To deliver the Dox to cells, the GP pellets bound to Dox were resuspended in 
DMEM and added to the 3T3-D1 cells.  To determine the GP mediated uptake of Dox by 
3T3-D1 cells, the cells were evaluated by fluorescent microscopy.  Figure 25C shows the 
difference in fluorescence based on uptake of unmodified GP and tRNA-DAP-GP. 
The anionic GPs were able to bind Dox in a moderate amount.  Additionally, the 
anionic GPs were able to successfully deliver Dox to cells; however, the amount of Dox 
delivered to the NIH 3T3-D1 cells is limited by the binding capacity of the GPs.  Without 
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more than moderate binding of Dox by anionic GPs, the expected results of the slowing 
of cell growth and eventual cell death will not be attained. 
4. Click Chemistry Modifications of GPs 
To determine the success of the click chemistry reaction, the particles were 
evaluate using fluorescent microscopy.  The click chemistry reaction was used to modify 
the surface functionality of the GPs.  The GPs synthesized using the click chemistry 
method included a positive control of GP and a negative control of azido-GP.  Both 
particles were able to absorb the r-tRNA/PEI core and show red fluorescence inside the 
particles.  However, only the surface of the GP was able to react with the f-alkyne to 
show green fluorescence of the surface of the particle (Figure 26). 
The click chemistry reaction is a very selective reaction.  In the past, the reaction 
to attach polymers and hydrocarbons to the surface would destroy the polymers 
encapsulated inside the particles.  If the surface was derivatized first, the loading of the 
inside of the GP was restricted.  This reaction has successfully loaded a rhodamine 




The synthesized library of cationic-GPs bound fluorescent anionic polystyrene 
nanoparticles and nucleic acids (siRNA, DNA, tRNA).  The PEI-GPs (10k and 25k) as 
well as the Q-GP tended to have the highest binding capacity for both the nanoparticles 
and the nucleic acids.  The PLL-GP exhibited very low levels of binding, nearly 
synonymous with the unmodified GP.  The cationic GPs also functionally delivered GFP 
expressing plasmid DNA into GP-phagocytic cells leading to efficient transfection.  The 
CN-GP provided the best transfection efficiency due to its moderately tight binding of the 
plasmid DNA. 
The library of anionic-GPs bound fluorescent cationic latex nanoparticles.  The 
nanoparticle aggregation did not allow for accurate fluorescence readings or binding 
capacity measurements; the confirmation of the binding data was accomplished by 
qualitative microscopy.  Additionally, the anionic GPs bound the soluble polymer 
rhodamine-10k PEI and the cancer chemotherapeutic drug doxorubicin.  Binding of Dox 
provided targeted drug delivery into GP-phagocytic cells. The anionic alginate (Alg-
DAP-GP and AlgL-DAP-GP) tended to show the highest binding capacity for the 
nanoparticles, polymers, and the drug.  The anionic GPs with tRNA on the surface 
(tRNA-GP and tRNA-DAP-GP) showed a moderate binding capacity for all payloads.   
Of the anionic GPs synthesized with DAP, the dextran sulfate and heparin GPs (DS-
DAP-GP and Hep-DAP-GP) showed the lowest binding capacity for all payloads. The 
alginate and tRNA coupling reactions to DAP-GP using the EDC and sulfoSANPAH 
crosslinkers, respectively, are more efficient than reductive amination of Hep and DS.  
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Particles showing little to no binding capacity included the alginate, dextran sulfate, and 
heparin particles synthesized without DAP (Alg-GP, AlgL-GP, DS-GP, and Hep-GP). 
In conclusion, moderate success was achieved in the synthesis of a working 
library of cationic and anionic glucan particles.  The particles were able to bind ionic 
nanoparticles, polymers, and drugs for delivery to cells.  The binding capacity of few 
particles (25k PEI-GP, Q-GP, Alg-DAP-GP) was exceptional.  Most particles showed 
moderate binding, and few showed little to no binding (PLL-GP, DS-GP, Hep-GP).  
Also, the modified glucan particles tended to bind payloads well, but the release of the 
payloads was sporadic and unable to be quantified.  The particles with high binding 
capacities were successful in delivery of payloads to cells.  However, the amount of 
payload, specifically Dox, bound to the particles was not enough to cause the expected 
slow of cell growth and eventual cell death.  Improvements in these particles (Future 
Work) will take steps toward creating an ideal particle that can successfully and 




Future work regarding the synthesis and analysis of surface derivatized glucan 
particles will include synthesizing surface derivatized GPs with pH sensitive, glutathione, 
or redox sensitive groups to control nanoparticle and drug release.   
Additionally, work will be done to address problems such as the synthesis and 
analysis of the DAP-GP particle.  DAP-GP should exhibit a higher amine content in a test 
such as the ninhydrin assay.  However, tests have show that the amine content found in 
DAP-GP is similar to and occasionally lower than the unmodified GP.  It is speculated 
that the size of DAP forces it to be embedded in the GP matrix.  If embedded in the 
matrix, the ninhydrin cannot reach it, the reaction does not occur, and a low amine 
content level is observed.  Extending the hydrocarbon chain on the surface of the particle 
using a compound like polyethylene glycol (PEG) will make the amine group of DAP 
more visible and more likely to react with ninhydrin.   
Additional work is required to optimize use of cationic GPs for DNA transfection 
and siRNA delivery. Future work with anionic GPs will also be carried out to optimize 
Dox binding and delivery to macrophage cells.   
Future improvements of the surface modification of cationic and anionic glucan 
particles will strive to create the ideal particle, which will not aggregate, can bind payload 
successfully in a significant amount, release the payload inside of cells with β-glucan 
receptors, and be easily degraded by the human body.  Because the surface of the 
particles is cationic or anionic, a wide range of payloads or drugs can be electrostatically 
bound to the surface of the particles.  The applications of these particles are not limited to 
cancer or chemotherapy drugs.  The ideal glucan particle, because it is derived from 
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Bakers yeast, can provide a lower-cost, non-toxic drug delivery system for many types of 
drugs, possibly making the medical treatment for many diseases and conditions more 












Glucan Mannan Particle  
(GMP) 
Yeast Chitin Particle 
(YCP) 
Glucan 80% 40% 40-50% 
Mannan <1% 40% 0% 
Chitin 2-4% 2-4% 40-50% 
 
Figure 1 - Glucan Particle Basics: A, Schematic representation  
of Glucan Particle (GP) synthesis.  B, Types and Compositions of  












Figure 2 - GP Drug Delivery Methods: A, Layer-by-layer (LbL) 
approach for drug encapsulation inside the hollow chamber of the 
glucan particle.  B, Possible surface derivatization ideas for 
electrostatic binding of drug particles.  This project deals with 







Chemical Abbreviation CAS No. (Product #) Supplier 
Potassium Periodate KIO4 7790-21-8 Sigma Aldrich 
Polyethyleneimine (10k) 10k PEI 9002-98-6 Sigma Aldrich 
Polyethyleneimine (25k) 25k PEI 9002-98-6 Sigma Aldrich 
Chitosan from crab shells,  
minimum 85% deacetylated CN 9012-76-4 Sigma Aldrich 
Poly-L-lysine Hydrobromide PLL 25988-63-0 Sigma Aldrich 
Sodium Borohydride NaBH4 16940-66-2 EMD 
Glycidyltrimethylammonium Chloride GTMAC 3033-77-0 Sigma Aldrich 
1,3-diaminopropane DAP 109-76-2 Sigma Aldrich 
Sodium Alginate F200  Alg 95328-14-6 Multi-Kem Corp. (Ridgefield, NJ) 
Sodium Alginate F200L AlgL  Multi-Kem Corp. (Ridgefield, NJ) 
1-ethyl-3- 




sulfoSANPAH 102568-43-4 Pierce Chemicals (Rockford, IL) 




Heparin sodium salt from porcine 
intestinal mucosa Hep 9041-08-1 Sigma Aldrich 
Ninhydrin  485-47-2 Sigma Aldrich 
Glycine  56-40-6 Sigma Aldrich 
FluoSpheres® Size Kit #1,  
Carboxylate modified microspheres,  
red fluorescent (0.02, 0.1, 0.2, 0.5, 1, 
and 2 µm in diameter) 
r-PS (F8887) Invitrogen 
Latex Beads, amine modified 
polystyrene, fluorescent orange 
(0.1 and 1 µm in diameter) 
Latex (L9904) Sigma Aldrich 






Dox 29042-30-6 Sigma Aldrich 
Copper (II) Sulfate CuSO4 7758-98-7 Sigma Aldrich 
(+) sodium-L-ascorbate  134-03-2 Sigma Aldrich 
Oregon Green 488 alkyne 6-isomer f-alkyne (O10181) Invitrogen 
Figure 3 - Materials: All materials used in the project.  Also 









Figure 5 - Fluorescence of Polystyrene Nanoparticles: A, 
Excitation of fluorescent polystyrene nanoparticles.  B, Emission 





























Figure 5 - Fluorescence of Latex Nanoparticles: A, Excitation of 
















Polymer Abbreviation % w/v TP mL TP mmol polymer mL Water 
10k PEI 10kPEI-GP 1 42.4 0.0424 2.6 
25k PEI 25kPEI-GP 5 22.4 0.0448 22.6 
Sigma Chitosan CN-GP 1 42.1 0.0042 2.9 
PLL PLL-GP 1 10.0 0.0213 4.0 
 
 
GP Sample GTMAC/GP ratio (µL/mg GP) mg GP µL GTMAC 
mmol GTMAC 
mg GP µL Water 
GP 2 5 10 0.0149 490 
GP 20 5 100 0.1490 400 
GP 50 5 250 0.3726 250 
GP 100 5 500 0.7452 0 
CN-GP 20 5 100 0.1490 400 
 
Figure 6 - Synthesis of Cationic GPs: A, Synthesis of non-







Polymer % TP mL TP mmol DAP mL Water 
DAP 0.1 3.1 0.0418 41.9 
 
 
Polymer mL Alg mL EDC (10 mg/mL) 
mL 
MES Buffer mL DAP-GP 
Alg F-200 8 8.4 11.6 20 
Alg F-200L 8 8.4 11.6 20 
 
 
Sample mg Sample µL sulfoSANPAH mL tRNA 
tRNA-GP 10 500 5 






Polymer mL Polymer mL DAP-GP 
DS  20 20 
Hep  10 20 
 
Figure 7 – Synthesis of Anionic GPs: A, Synthesis of 
Diaminopropane-GP.  B, Synthesis of Alginate (Carboxyl) GPs.  
C, Synthesis of tRNA (Phosphate) GPs.  D, Synthesis of Dextran 










Figure 8 - Ninhydrin Reaction Scheme: The reaction of 
ninhydrin with an amino acid to form Ruhemann’s Purple, a  




Core µL tRNA µL 0.1% PEI 
GP-(R)tRNA/P 5 of 10 mg/mL 30 
N3-GP-(R)tRNA/P 5 of 10 mg/mL 30 
 
Figure 9 – Click Chemistry Derivatizations of GPs: Synthesis  
of Click Chemistry Particles  
 48 
 
GP Sample     µmol NH2____         mg Cationic GP 
GP 0.0456 ± 0.010 
10k PEI-GP 0.0820 ± 0.004 
25k PEI-GP 0.0865 ± 0.006 
CN-GP 0.0728 ± 0.006 
DAP-GP 0.0278 ± 0.015 
PLL-GP 0.1185 ± 0.011 
Q-GP 0.0683 ± 0.021 
 
Figure 10 - Ninhydrin Assay Results: Results of the Ninhydrin 




GP Sample Zeta Potential  Maximum 
GP -2.09 
10k PEI-GP 17.6 









Figure 11 - Zeta Potential Results for Cationic GPs: A, Zeta 
potentials for all synthesized cationic GPs.  B, A sample plot of the 






















Figure 12 - Zeta Potential Results for Anionic GPs: A, Zeta 
potentials for all synthesized anionic GPs.  B, A sample plot of the 







       
 
Figure 13 - Cationic GPs Binding Results with 20nm r-PS: A, 
Binding Capacity Graph showing the calculated binding capacity 
for cationic GPs bound to fluorescent 20nm polystyrene 
nanoparticles at a ratio of 100 NP/GP.  B, Fluorescent microscopy 
























       
 
Figure 14 - Cationic GPs Binding Results with 100nm r-PS: A, 
Binding Capacity Graph showing the calculated binding capacity 
for cationic GPs bound to fluorescent 100nm polystyrene 
nanoparticles at a ratio of 100 NP/GP.  B, Fluorescent microscopy 



























       
 
Figure 15 - Cationic GPs Binding Results with 200nm r-PS: A, 
Binding Capacity Graph showing the calculated binding capacity 
for cationic GPs bound to fluorescent 200nm polystyrene 
nanoparticles at a ratio of 100 NP/GP.  B, Fluorescent microscopy 



























Figure 16 - FACS Results for Cationic GPs with 200nm r-PS: 
A, FACS graph for unmodified GP with 200nm r-PS.  B, FACS 







GP Sample Zeta Potential  Maximum  
Zeta Potential Maximum  
with nanoparticles 
GP -2.09 -1.70 
10k PEI-GP 17.6 -13.2 
25k PEI-GP 19.2 -24.2 
CN-GP 21.0 -24.0 
PLL-GP 9.01 -46.6 





Figure 17 – Zeta Potential Results +/- 200nm r-PS: A, Zeta 
Potential measurements for cationic GPs and cationic GPs bound 
to 200nm r-PS nanoparticles.  B, A sample plot of the zeta 






       
 
         
 
 
         
 
Figure 18 - Cationic GP Binding Results with Larger r-PS 
Nanoparticles: A, GP, 10k PEI-GP, and CN-GP bound to 500nm 
polystyrene nanoparticles.  B, GP, 10k PEI-GP, and CN-GP bound 










     
 
GP Sample Zeta Potential Maximum 
Zeta Potenetial Maximum  
with nanoparticles 
GP -2.09 -8.73 
DS-DAP-GP 12.1 -3.70 
Hep-DAP-GP 10.0 -0.79 
AlgL-DAP-GP -18.2 -3.32 
tRNA-DAP-GP -16.8 -6.56 
 
Figure 19 - Anionic GP Binding Results with 100nm Latex: A, 
Binding Capacity Graph showing the calculated binding capacity 
for anionic GPs bound to fluorescent 100nm latex nanoparticles at 
a ratio of 10 NP/GP.  B, Fluorescent microscopy images for 200nm 
r-PS bound to GP and AlgL-DAP-GP.  C, Zeta Potential 










       
 
 
GP Sample Zeta Potential Maximum Zeta Potential Maximum  with polymer 
GP -2.09 -8.10 
10k PEI-GP 17.6 -22.2 
25k PEI-GP 19.2  3.40 
CN-GP 21.0 -11.5 
Q-GP 19.6 -20.0 
 
Figure 20 - Cationic GP Binding Results with Cy3-siRNA: A, 
Binding Capacity Graph showing the calculated binding capacity 
for cationic GPs bound to fluorescent Cy3-siRNA.  B, Fluorescent 
microscopy images for Cy3-siRNA bound to GP, 25k PEI-GP, and 
Q-GP.  C, Zeta Potential measurements for cationic GPs and 




























    
 
Figure 21 - Cationic GP Binding Results with r-DNA: A, 
Binding Capacity Graph showing the calculated binding capacity 
for cationic GPs bound to fluorescent r-DNA.  B, Fluorescent 


























         
 
Figure 22 - Cationic GP Binding Results with r-tRNA: A, 
Binding Capacity Graph showing the calculated binding capacity 
for cationic GPs bound to fluorescent r-tRNA.  B, Fluorescent 









       
 
Figure 23 - Anionic GP Binding Results with r-10k PEI: A, 
Binding Capacity Graph showing the calculated binding capacity 
for anionic GPs bound to fluorescent r-10k PEI.  B, Fluorescent 








GP Sample Transfection Efficiency (%) 
GP 3.5 
10k PEI-GP 0.5 






GP Sample DNA Concentration (µg/1x106 particles) Transfection Efficiency (%) 
CN-GP 0.050 25.8 
CN-GP 0.125 5.5 
CN-GP 0.250 3.8 




     
 
Figure 24 - DNA Transfection Results: A, Transfection 
efficiency of cationic GPs using gWizGFP DNA.  B, Transfection 
Efficiency of CN-GP with varying concentrations of gWizGFP 
DNA.  C, Fluorescent microscopy images of 3T3-D1 cells 









        
 
      
 
Figure 25 - Dox Binding and Uptake: A, Binding Capacity Graph 
showing the calculated binding capacity for anionic GPs bound to 
fluorescent Dox.  B, Fluorescent microscopy images for Dox 
bound to GP and tRNA-DAP-GP.  C, Fluorescent microscopy 









     
 
 
    
 
Figure 26 – Click Chemistry Results: A, GP and N3-GP after 
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